期刊文献+

曲前列尼尔治疗特发性肺动脉高压引起血小板减少1例

Thrombocytopenia caused by treprostanil in the treatment of idiopathic pulmonary arterial hypertension:a case report
原文传递
导出
摘要 28岁女性患者,以活动后气促、心悸为主要临床表现,完善血常规、肝肾功能、传染病标志物、风湿免疫、心脏超声、胸部CT、肺动脉CT、右心导管、肺功能等检查,确诊特发性肺动脉高压。曲前列尼尔治疗肺动脉高压引起血小板减少的报道较少,在治疗中应注意监测患者血小板计数,以防止出血发生。 A 28-year-old female patient,whose main clinical manifestations were dyspnea and palpitations after exercise,was diagnosed with idiopathic pulmonary arterial hypertension after blood routine,liver and kidney function,markers of infectious diseases,rheumatism immunity,cardiac ultrasound,chest CT,pulmonary artery CT,right cardiac catheterization,and pulmonary function.There are few reports of thrombocytopenia caused by treprostanil in the treatment of pulmonary arterial hypertension,we should pay attention to monitoring the change of platelet count to prevent bleeding.
作者 张灿 常开丽 刘演龙 鲁一兵 周旭 戴海龙 ZHANG Can;CHANG Kaili;LIU Yanlong;LU Yibing;ZHOU Xu;DAI Hailong(Clinical Medicine Center and Key Laboratory for Cardiovascular Disease of Yunnan Province,Department of Cardiology,Yan'an Affiliated Hospital of Kunming Medical University,Kunming,650051,China)
出处 《临床心血管病杂志》 CAS 北大核心 2023年第2期160-162,共3页 Journal of Clinical Cardiology
基金 国家自然科学基金项目(No:82060018、81700438) 云南省自然科学基金项目[No:202101AS070043、2019FE001(-269)]。
关键词 肺动脉高压 前列环素 曲前列尼尔 血小板减少 pulmonary arterial hypertension prostacyclin treprostanil thrombocytopenia
  • 相关文献

参考文献9

二级参考文献111

  • 1侯明.免疫性血小板减少症的治疗进展[J].临床血液学杂志,2020,33(1):6-9. 被引量:33
  • 2Wei-GuoDong,Chun-ShengCheng,Shao-PingLiu,Jie-PingYu.Epidemiology of peptic ulcer disease in Wuhan area of China from 1997 to 2002[J].World Journal of Gastroenterology,2004,10(22):3377-3379. 被引量:7
  • 3RUBIN LJ. Primary pulmonary hypertension[ J]. N Engl J Med,1997,336(2) :111 - 117.
  • 4HUMBERT M,SITBON 0,SIM0NNEAU G. Treatment of pulmo-nary arterial hypertension [ J ]. N Engl J Med ^2004 , 351 ( 14):1425 - 1436.
  • 5CLAPP LH, FINNEY P,TURCATO S, et al. Differential effectsof stable prostacyclin analogs on smooth muscle proliferation andcyclic AMP generation in human pulmonary artery [J]. Am J Re-spir Cell Mol 5w/,2002 ,26(2) :194 -201.
  • 6BARST RJ, RUBIN LJ, LONG WAal. A comparison of con-tinuous intravenous epoprostenol ( prostacyclin) with conventionaltherapy for primary pulmonary hypertension[ J] ? N Engl J Med,1996,334(5) :296 -301.
  • 7TUDEH RM, COOL CD, GERACI MW.ei al. Prostacyclin syn-thase expression is decreased in lungs from patients with severepulmonary hypertension [ J ]. Am J Respir Crit Care Medy 1999 ,159(6) :1925 - 1932.
  • 8WHITTLE BJ, SILVERSTEIN AM, MOTTO LA DM,et al. Bind-ing and activity of the prostacyclin receptor (IP) agonists,trepro-stinil and iloprost, at human prostanoid receptors : treprostinil is apotent DPI and EP2 agonist [ J ]. Biochem Pharmacol, 2012 , 84(1);68 -75.
  • 9VANE JR,BOTTING RM. Pharmacodynamic profile of prostacyc-lin[J]. Am J Cardiol ,1995,15 (3) :3A - 10A.
  • 10LI Y, CONNOLLY M,NAGARAJ C,et al. Peroxisome prolifera-tor-activated receptor-b/d, the acute signaling factor in prostacyc-lin-induced pulmonary vasodilation[ J] . Am J Respir Cell Mol Bi-o/,2012,46(3) :372 -379.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部